X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Recommendation of “Hold” by Brokerages

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have been given an average recommendation of “Hold” by the five analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $34.50.

A number of research analysts recently issued reports on XFOR shares. Wall Street Zen lowered X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Stifel Nicolaus set a $10.00 target price on X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Zacks Research cut shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th.

Institutional Trading of X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in XFOR. Indivisible Partners purchased a new stake in X4 Pharmaceuticals in the 4th quarter valued at approximately $40,000. Palumbo Wealth Management LLC grew its stake in X4 Pharmaceuticals by 18.9% in the 4th quarter. Palumbo Wealth Management LLC now owns 113,357 shares of the company’s stock valued at $453,000 after acquiring an additional 18,030 shares during the last quarter. Acorn Capital Advisors LLC grew its position in shares of X4 Pharmaceuticals by 77.8% in the third quarter. Acorn Capital Advisors LLC now owns 273,349 shares of the company’s stock valued at $935,000 after purchasing an additional 119,619 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in X4 Pharmaceuticals during the 3rd quarter valued at $7,621,000. Finally, Kingdon Capital Management L.L.C. grew its holdings in X4 Pharmaceuticals by 300.0% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after buying an additional 700,000 shares during the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Trading Down 3.8%

Shares of X4 Pharmaceuticals stock opened at $3.85 on Friday. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23. The firm’s 50-day moving average price is $3.83 and its 200 day moving average price is $3.38. The firm has a market capitalization of $336.64 million, a PE ratio of -0.38 and a beta of 0.46. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $19.69.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.10. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%.The firm had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $2.05 million. On average, sell-side analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.